FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:499-505 February 19, 1998 Number 8 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The rate of clearance of antileukemic agents differs by a factor of 3 to 10 among children with acute lymphoblastic leukemia. We hypothesized that the outcome of treatment would be improved if doses were individualized to prevent low systemic exposure to the drugs in patients with fast drug clearance.

Methods We stratified and randomly assigned 182 children with newly diagnosed acute lymphoblastic leukemia to postremission regimens that included high-dose methotrexate and teniposide plus cytarabine. The doses of these drugs were based on body-surface area (in the conventional-therapy group) or the rates of clearance of the three medications in each patient (in the individualized-treatment group). In the individualized-treatment group, doses were increased in patients with rapid clearance and decreased in patients with very slow clearance.

Results Patients who received individualized doses had significantly fewer courses of treatment with systemic exposures below the target range than did patients who received conventional doses (P<0.001 for each medication). Among the patients with B-lineage leukemia, those who received individualized therapy had a significantly better outcome than those given conventional therapy (P = 0.02); the mean (±SE) rates of continuous complete remission at five years were 76±6 percent and 66±7 percent, respectively. There was no significant difference between treatments for patients with T-lineage leukemia (P = 0.54). In a proportional-hazards model, the time-dependent systemic exposure to methotrexate, but not to teniposide or cytarabine, was significantly related to the risk of early relapse in children with B-lineage leukemia.

Conclusions Adjusting the dose of methotrexate to account for the patient's ability to clear the drug can improve the outcome in children with B-lineage acute lymphoblastic leukemia.

Source Information

From the Departments of Pharmaceutical Sciences (W.E.E., M.V.R., J.H.R., W.R.C.), Biostatistics and Epidemiology (J.M.B.), and Hematology–Oncology (C.-H.P.), St. Jude Children's Research Hospital; and the Colleges of Pharmacy (W.E.E., M.V.R., J.H.R., W.R.C.) and Medicine (W.E.E., C.-H.P.), University of Tennessee — both in Memphis.

Address reprint requests to Dr. Evans at St. Jude Children's Research Hospital, 332 N. Lauderdale St., Memphis, TN 38105.

Full Text of this Article

This article has been cited by other articles:

• Tucci, F., Arico, M. (2008). Treatment of pediatric acute lymphoblastic leukemia. haematol 93: 1124-1128 [Full Text]  
• McDonald, G B, Frieze, D (2008). A problem-oriented approach to liver disease in oncology patients. Gut 57: 987-1003 [Full Text]  
• Jones, T. S., Kaste, S. C., Liu, W., Cheng, C., Yang, W., Tantisira, K. G., Pui, C.-H., Relling, M. V. (2008). CRHR1 Polymorphisms Predict Bone Density in Survivors of Acute Lymphoblastic Leukemia. JCO 26: 3031-3037 [Abstract] [Full Text]  
• Walko, C. M., McLeod, H. L. (2008). Will We Ever Be Ready for Blood Level-Guided Therapy?. JCO 26: 2078-2079 [Full Text]  
• Oudot, C., Auclerc, M.-F., Levy, V., Porcher, R., Piguet, C., Perel, Y., Gandemer, V., Debre, M., Vermylen, C., Pautard, B., Berger, C., Schmitt, C., Leblanc, T., Cayuela, J.-M., Socie, G., Michel, G., Leverger, G., Baruchel, A. (2008). Prognostic Factors for Leukemic Induction Failure in Children With Acute Lymphoblastic Leukemia and Outcome After Salvage Therapy: The FRALLE 93 Study. JCO 26: 1496-1503 [Abstract] [Full Text]  
• Alnaim, L. (2007). Therapeutic drug monitoring of cancer chemotherapy. J Oncol Pharm Pract 13: 207-221 [Abstract]  
• Mathijssen, R. H.J., de Jong, F. A., Loos, W. J., van der Bol, J. M., Verweij, J., Sparreboom, A. (2007). Flat-Fixed Dosing Versus Body Surface Area Based Dosing of Anticancer Drugs in Adults: Does It Make a Difference?. The Oncologist 12: 913-923 [Abstract] [Full Text]  
• Hijiya, N., Hudson, M. M., Lensing, S., Zacher, M., Onciu, M., Behm, F. G., Razzouk, B. I., Ribeiro, R. C., Rubnitz, J. E., Sandlund, J. T., Rivera, G. K., Evans, W. E., Relling, M. V., Pui, C.-H. (2007). Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic Leukemia. JAMA 297: 1207-1215 [Abstract] [Full Text]  
• Hijiya, N., Panetta, J. C., Zhou, Y., Kyzer, E. P., Howard, S. C., Jeha, S., Razzouk, B. I., Ribeiro, R. C., Rubnitz, J. E., Hudson, M. M., Sandlund, J. T., Pui, C.-H., Relling, M. V. (2006). Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood 108: 3997-4002 [Abstract] [Full Text]  
• Kloft, C., Wallin, J., Henningsson, A., Chatelut, E., Karlsson, M. O. (2006). Population Pharmacokinetic-Pharmacodynamic Model for Neutropenia with Patient Subgroup Identification: Comparison across Anticancer Drugs.. Clin. Cancer Res. 12: 5481-5490 [Abstract] [Full Text]  
• Salinger, D. H., McCune, J. S., Ren, A. G., Shen, D. D., Slattery, J. T., Phillips, B., McDonald, G. B., Vicini, P. (2006). Real-time Dose Adjustment of Cyclophosphamide in a Preparative Regimen for Hematopoietic Cell Transplant: A Bayesian Pharmacokinetic Approach.. Clin. Cancer Res. 12: 4888-4898 [Abstract] [Full Text]  
• Parshuram, C. S, Dupuis, L L., To, T., Weitzman, S. S, Koren, G., Laupacis, A. (2006). Occurrence and Impact of Unanticipated Variation in Intravenous Methotrexate Dosing. The Annals of Pharmacotherapy 40: 805-811 [Abstract] [Full Text]  
• Sterba, J., Dusek, L., Demlova, R., Valik, D. (2006). Pretreatment Plasma Folate Modulates the Pharmacodynamic Effect of High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: "Folate Overrescue" Concept Revisited. Clin. Chem. 52: 692-700 [Abstract] [Full Text]  
• Pui, C.-H., Evans, W. E. (2006). Treatment of Acute Lymphoblastic Leukemia. NEJM 354: 166-178 [Full Text]  
• Pui, C.-H., Pei, D., Sandlund, J. T., Campana, D., Ribeiro, R. C., Razzouk, B. I., Rubnitz, J. E., Howard, S. C., Hijiya, N., Jeha, S., Cheng, C., Downing, J. R., Evans, W. E., Relling, M. V., Hudson, M. (2005). Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia. JCO 23: 7936-7941 [Abstract] [Full Text]  
• Reddick, W. E., Glass, J. O., Helton, K. J., Langston, J. W., Li, C.-S., Pui, C.-H. (2005). A Quantitative MR Imaging Assessment of Leukoencephalopathy in Children Treated for Acute Lymphoblastic Leukemia without Irradiation. Am. J. Neuroradiol. 26: 2371-2377 [Abstract] [Full Text]  
• Petros, W. P., Hopkins, P. J., Spruill, S., Broadwater, G., Vredenburgh, J. J., Colvin, O. M., Peters, W. P., Jones, R. B., Hall, J., Marks, J. R. (2005). Associations Between Drug Metabolism Genotype, Chemotherapy Pharmacokinetics, and Overall Survival in Patients With Breast Cancer. JCO 23: 6117-6125 [Abstract] [Full Text]  
• Zwaan, M. (2005). Toward individualized dosing in pediatric ALL. Blood 105: 4544-4545 [Full Text]  
• Rocha, J. C. C., Cheng, C., Liu, W., Kishi, S., Das, S., Cook, E. H., Sandlund, J. T., Rubnitz, J., Ribeiro, R., Campana, D., Pui, C.-H., Evans, W. E., Relling, M. V. (2005). Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105: 4752-4758 [Abstract] [Full Text]  
• Boesler, B., Czock, D., Keller, F., Griesshammer, M., Seufferlein, T., Karges, W., Rasche, F. M. (2005). Clinical course of haemodialysis patients with malignancies and dose-adjusted chemotherapy. Nephrol Dial Transplant 20: 1187-1191 [Abstract] [Full Text]  
• Reddick, W. E., Glass, J. O., Helton, K. J., Langston, J. W., Xiong, X., Wu, S., Pui, C.-H. (2005). Prevalence of Leukoencephalopathy in Children Treated for Acute Lymphoblastic Leukemia with High-Dose Methotrexate. Am. J. Neuroradiol. 26: 1263-1269 [Abstract] [Full Text]  
• Sandstrom, M., Lindman, H., Nygren, P., Lidbrink, E., Bergh, J., Karlsson, M.O. (2005). Model Describing the Relationship Between Pharmacokinetics and Hematologic Toxicity of the Epirubicin-Docetaxel Regimen in Breast Cancer Patients. JCO 23: 413-421 [Abstract] [Full Text]  
• Yule, S. M., Price, L., McMahon, A. D., Pearson, A. D. J., Boddy, A. V. (2004). Cyclophosphamide Metabolism in Children with Non-Hodgkin's Lymphoma. Clin. Cancer Res. 10: 455-460 [Abstract] [Full Text]  
• Pui, C.-H., Cheng, C., Leung, W., Rai, S. N., Rivera, G. K., Sandlund, J. T., Ribeiro, R. C., Relling, M. V., Kun, L. E., Evans, W. E., Hudson, M. M. (2003). Extended Follow-up of Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia. NEJM 349: 640-649 [Abstract] [Full Text]  
• Schmiegelow, K., Bjork, O., Glomstein, A., Gustafsson, G., Keiding, N., Kristinsson, J., Makipernaa, A., Rosthoj, S., Szumlanski, C., Sorensen, T. M, Weinshilboum, R. (2003). Intensification of Mercaptopurine/Methotrexate Maintenance Chemotherapy May Increase the Risk of Relapse for Some Children With Acute Lymphoblastic Leukemia. JCO 21: 1332-1339 [Abstract] [Full Text]  
• Burger, B., Zimmermann, M., Mann, G., Kuhl, J., Loning, L., Riehm, H., Reiter, A., Schrappe, M. (2003). Diagnostic Cerebrospinal Fluid Examination in Children With Acute Lymphoblastic Leukemia: Significance of Low Leukocyte Counts With Blasts or Traumatic Lumbar Puncture. JCO 21: 184-188 [Abstract] [Full Text]  
• Leung, W., Rose, S. R., Zhou, Y., Hancock, M. L., Burstein, S., Schriock, E. A., Lustig, R., Danish, R. K., Evans, W. E., Hudson, M. M., Pui, C.-H. (2002). Outcomes of Growth Hormone Replacement Therapy in Survivors of Childhood Acute Lymphoblastic Leukemia. JCO 20: 2959-2964 [Abstract] [Full Text]  
• Sandlund, J. T., Harrison, P. L., Rivera, G., Behm, F. G., Head, D., Boyett, J., Rubnitz, J. E., Gajjar, A., Raimondi, S., Ribeiro, R., Hudson, M., Relling, M., Evans, W., Pui, C.-H. (2002). Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood 100: 43-47 [Abstract] [Full Text]  
• Coustan-Smith, E., Sancho, J., Behm, F. G., Hancock, M. L., Razzouk, B. I., Ribeiro, R. C., Rivera, G. K., Rubnitz, J. E., Sandlund, J. T., Pui, C.-H., Campana, D. (2002). Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 100: 52-58 [Abstract] [Full Text]  
• Bergh, J. (2002). Is pharmacokinetically guided chemotherapy dosage a better way forward?. Ann Oncol 13: 343-344 [Full Text]  
• Petros, W. P., Broadwater, G., Berry, D., Jones, R. B., Vredenburgh, J. J., Gilbert, C. J., Gibbs, J. P., Colvin, O. M., Peters, W. P. (2002). Association of High-dose Cyclophosphamide, Cisplatin, and Carmustine Pharmacokinetics with Survival, Toxicity, and Dosing Weight in Patients with Primary Breast Cancer. Clin. Cancer Res. 8: 698-705 [Abstract] [Full Text]  
• Kebelmann-Betzing, C., Seeger, K., Wolf, R., Henze, G., Gajjar, A., Pui, C.-H. (2001). Traumatic lumbar puncture at diagnosis and outcome in childhood acute lymphoblastic leukemia. Blood 98: 3496-3497 [Full Text]  
• Evans, W. E., Hon, Y. Y., Bomgaars, L., Coutre, S., Holdsworth, M., Janco, R., Kalwinsky, D., Keller, F., Khatib, Z., Margolin, J., Murray, J., Quinn, J., Ravindranath, Y., Ritchey, K., Roberts, W., Rogers, Z. R., Schiff, D., Steuber, C., Tucci, F., Kornegay, N., Krynetski, E. Y., Relling, M. V. (2001). Preponderance of Thiopurine S-Methyltransferase Deficiency and Heterozygosity Among Patients Intolerant to Mercaptopurine or Azathioprine. JCO 19: 2293-2301 [Abstract] [Full Text]  
• Gajjar, A., Harrison, P. L., Sandlund, J. T., Rivera, G. K., Ribeiro, R. C., Rubnitz, J. E., Razzouk, B., Relling, M. V., Evans, W. E., Boyett, J. M., Pui, C.-H. (2000). Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood 96: 3381-3384 [Abstract] [Full Text]  
• Coustan-Smith, E., Sancho, J., Hancock, M. L., Boyett, J. M., Behm, F. G., Raimondi, S. C., Sandlund, J. T., Rivera, G. K., Rubnitz, J. E., Ribeiro, R. C., Pui, C.-H., Campana, D. (2000). Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96: 2691-2696 [Abstract] [Full Text]  
• Friedmann, A. M., Weinstein, H. J. (2000). The Role of Prognostic Features in the Treatment of Childhood Acute Lymphoblastic Leukemia. The Oncologist 5: 321-328 [Abstract] [Full Text]  
• McLeod, H. L., Cassidy, J., Powrie, R. H., Priest, D. G., Zorbas, M. A., Synold, T. W., Shibata, S., Spicer, D., Bissett, D., Pithavala, Y. K., Collier, M. A., Paradiso, L. J., Roberts, J. D. (2000). Pharmacokinetic and Pharmacodynamic Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitor AG2034. Clin. Cancer Res. 6: 2677-2684 [Abstract] [Full Text]  
• Schrappe, M., Reiter, A., Ludwig, W.-D., Harbott, J., Zimmermann, M., Hiddemann, W., Niemeyer, C., Henze, G., Feldges, A., Zintl, F., Kornhuber, B., Ritter, J., Welte, K., Gadner, H., Riehm, H. (2000). Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood 95: 3310-3322 [Abstract] [Full Text]  
• Collins, J. M. (2000). Cytochrome P-450 and Other Determinants of Pharmacokinetics, Toxicity, and Efficacy in Humans. Clin. Cancer Res. 6: 1203-1204 [Full Text]  
• Mahoney, D. H. Jr, Shuster, J. J., Nitschke, R., Lauer, S., Steuber, C. P., Camitta, B. (2000). Intensification With Intermediate-Dose Intravenous Methotrexate Is Effective Therapy for Children With Lower-Risk B-Precursor Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study. JCO 18: 1285-1294 [Abstract] [Full Text]  
• Kantarjian, H. M., O’Brien, S., Smith, T. L., Cortes, J., Giles, F. J., Beran, M., Pierce, S., Huh, Y., Andreeff, M., Koller, C., Ha, C. S., Keating, M. J., Murphy, S., Freireich, E. J. (2000). Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia. JCO 18: 547-547 [Abstract] [Full Text]  
• Eden, O B (2000). Therapeutic trials in childhood ALL: what's their future?. J. Clin. Pathol. 53: 55-59 [Full Text]  
• Felix, C. A., Lange, B. J., Chessells, J. M. (2000). Pediatric Acute Lymphoblastic Leukemia: Challenges and Controversies in 2000. ASH Education Book 2000: 285-302 [Abstract] [Full Text]  
• Relling, M. V., Hancock, M. L., Rivera, G. K., Sandlund, J. T., Ribeiro, R. C., Krynetski, E. Y., Pui, C.-H., Evans, W. E. (1999). Mercaptopurine Therapy Intolerance and Heterozygosity at the Thiopurine S-Methyltransferase Gene Locus. JNCI J Natl Cancer Inst 91: 2001-2008 [Abstract] [Full Text]  
• Rots, M. G., Pieters, R., Peters, G. J., van Zantwijk, C. H., Mauritz, R., Noordhuis, P., Willey, J. C., Hahlen, K., Creutzig, U., Janka-Schaub, G., Kaspers, G. J.L., Veerman, A. J.P., Jansen, G. (1999). Circumvention of Methotrexate Resistance in Childhood Leukemia Subtypes by Rationally Designed Antifolates. Blood 94: 3121-3128 [Abstract] [Full Text]  
• Evans, W. E., Relling, M. V. (1999). Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science 286: 487-491 [Abstract] [Full Text]  
• McLeod, H. L., Evans, W. E. (1999). Oral Cancer Chemotherapy: The Promise and the Pitfalls. Clin. Cancer Res. 5: 2669-2671 [Full Text]  
• Zecca, M., Pession, A., Messina, C., Bonetti, F., Favre, C., Prete, A., Cesaro, S., Porta, F., Mazzarino, I., Giorgiani, G., Rondelli, R., Locatelli, F. (1999). Total Body Irradiation, Thiotepa, and Cyclophosphamide as a Conditioning Regimen for Children With Acute Lymphoblastic Leukemia in First or Second Remission Undergoing Bone Marrow Transplantation With HLA-Identical Siblings. JCO 17: 1838-1838 [Abstract] [Full Text]  
• Relling, M. V., Hancock, M. L., Boyett, J. M., Pui, C.-H., Evans, W. E. (1999). Prognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia. Blood 93: 2817-2823 [Abstract] [Full Text]  
• Nieto, Y., Xu, X., Cagnoni, P. J., Matthes, S., Shpall, E. J., Bearman, S. I., Murphy, J., Jones, R. B. (1999). Nonpredictable Pharmacokinetic Behavior of High-Dose Cyclophosphamide in Combination with Cisplatin and 1,3-Bis(2-chloroethyl)-1-nitrosourea. Clin. Cancer Res. 5: 747-751 [Abstract] [Full Text]  
• Rowinsky, E. K., Jiroutek, M., Bonomi, P., Johnson, D., Baker, S. D. (1999). Paclitaxel Steady-State Plasma Concentration as a Determinant of Disease Outcome and Toxicity in Lung Cancer Patients Treated with Paclitaxel and Cisplatin. Clin. Cancer Res. 5: 767-774 [Abstract] [Full Text]  
• Pui, C.-H., Boyett, J. M., Relling, M. V., Harrison, P. L., Rivera, G. K., Behm, F. G., Sandlund, J. T., Ribeiro, R. C., Rubnitz, J. E., Gajjar, A., Evans, W. E. (1999). Sex Differences in Prognosis for Children With Acute Lymphoblastic Leukemia. JCO 17: 818-818 [Abstract] [Full Text]  
• Belkov, V. M., Krynetski, E. Y., Schuetz, J. D., Yanishevski, Y., Masson, E., Mathew, S., Raimondi, S., Pui, C.-H., Relling, M. V., Evans, W. E. (1999). Reduced Folate Carrier Expression in Acute Lymphoblastic Leukemia: A Mechanism for Ploidy but not Lineage Differences in Methotrexate Accumulation. Blood 93: 1643-1650 [Abstract] [Full Text]  
• Rots, M. G., Pieters, R., Kaspers, G.-J. L., van Zantwijk, C. H., Noordhuis, P., Mauritz, R., Veerman, A. J.P., Jansen, G., Peters, G. J. (1999). Differential Methotrexate Resistance in Childhood T- Versus Common/PreB-Acute Lymphoblastic Leukemia Can Be Measured by an In Situ Thymidylate Synthase Inhibition Assay, But Not by the MTT Assay. Blood 93: 1067-1074 [Abstract] [Full Text]  
• Coulthard, S. A., Howell, C., Robson, J., Hall, A. G. (1998). The Relationship Between Thiopurine Methyltransferase Activity and Genotype in Blasts From Patients With Acute Leukemia. Blood 92: 2856-2862 [Abstract] [Full Text]  
• Pui, C.-H., Evans, W. E. (1998). Acute Lymphoblastic Leukemia. NEJM 339: 605-615 [Full Text]